TY - JOUR
T1 - Leveraging the activity of tumor vaccines with cytotoxic chemotherapy
AU - Emens, Leisha
AU - Jaffee, Elizabeth M.
PY - 2005/9/15
Y1 - 2005/9/15
N2 - Engaging the power of the patient's own immune system to actively seek out and destroy transformed cells holds great promise for cancer therapy. Tumor vaccines offer the potential for preventing cancer in high-risk individuals, preventing disease relapse after diagnosis and initial therapy, and shifting the balance of the host-tumor interaction to mitigate the progression of advanced cancers. The therapeutic activity of tumor vaccines is limited by the sheer physical burden of the cancer itself, pathways of local immune tolerance and escape active within the tumor microenvironment, and superimposed potent systemic mechanisms of immune tolerance. In this review, we describe how cytotoxic chemotherapy can be integrated with tumor vaccines using unique doses and schedules to break down these barriers, releasing the full potential of the antitumor immune response to eradicate disease.
AB - Engaging the power of the patient's own immune system to actively seek out and destroy transformed cells holds great promise for cancer therapy. Tumor vaccines offer the potential for preventing cancer in high-risk individuals, preventing disease relapse after diagnosis and initial therapy, and shifting the balance of the host-tumor interaction to mitigate the progression of advanced cancers. The therapeutic activity of tumor vaccines is limited by the sheer physical burden of the cancer itself, pathways of local immune tolerance and escape active within the tumor microenvironment, and superimposed potent systemic mechanisms of immune tolerance. In this review, we describe how cytotoxic chemotherapy can be integrated with tumor vaccines using unique doses and schedules to break down these barriers, releasing the full potential of the antitumor immune response to eradicate disease.
UR - http://www.scopus.com/inward/record.url?scp=24944478531&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=24944478531&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-05-1797
DO - 10.1158/0008-5472.CAN-05-1797
M3 - Review article
C2 - 16166275
AN - SCOPUS:24944478531
SN - 0008-5472
VL - 65
SP - 8059
EP - 8064
JO - Cancer Research
JF - Cancer Research
IS - 18
ER -